ArticleInfection2026
Pathogen distribution and antimicrobial resistance in simple and complicated urinary tract infections in pediatric patients.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe assessed pathogens, risk factors, and antibiotic non-susceptibility (ANS) rates in order to optimize the empiric antibiotic therapy for children and adolescents admitted with urinary tract infection (UTI).
methodsA retrospective case-control study was conducted on children and adolescents aged 3 months to 18 years discharged with a complicated UTI (cUTI) diagnosis from two Israeli tertiary care pediatric centers (2018–2021). The control group included children and adolescents diagnosed with simple UTIs (sUTI) during the study period.
results234 children with a mean age of 3.8 years were included. Male sex and previous antibiotic treatment in the last 3 months (therapeutic and prophylactic) were significantly higher in the cUTI group (26.8% vs. 11.2%. and 59.8% vs. 9.9%, respectively). Escherichia coli was the most common pathogen, especially in sUTIs, while cUTIs showed a more diverse profile, including Pseudomonas aeruginosa. cUTIs were independent predictors of multidrug-resistant (MDR) and extended-spectrum b lactamases (ESBL) producing bacteria that comprise 23% of the enterobacteria in this group,
conclusionsOur findings emphasize the need for empirical treatment for cUTIs that include antipseudomonal agents and ESBL coverage. Cephalosporins are not optimal empiric treatment in this group, while amikacin demonstrated 100% susceptibility, making it more appropriate for initial empiric therapy. Ongoing surveillance is warranted to monitor antimicrobial resistance and guide appropriate empiric treatment.
Indexed as
Identifiers
41498908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.